DOSSIER · 13F-HR · Q2 2026

ARCH Venture Management, LLC

$1.1B in tracked AUM across 12 positions as of Q2 2026.

AV
CIK 0001274403 · last filed Jun 30, 2026
Total AUM
$1.1B
as of Q2 2026
Holdings
12
—
positions
Whale Score
79
79
strong
Activity
—
no data
changes this Q
AI Analysis · Q2 2026

Portfolio Overview

ARCH Venture Management’s 13F filing for the period ending September 30, 2025, reveals a highly concentrated, high-conviction portfolio with a distinct focus on early-stage and clinical-stage biotechnology. The firm manages approximately $384.90 million in assets across just 7 holdings, resulting in an average position size of roughly $55 million. This extreme lack of diversification—nearly 30% of the fund is allocated to a single security—indicates an investment ...

The portfolio experienced significant growth during the quarter, with total assets under management (AUM) increasing by 28.7%, rising from $299.11 million to $384.90 million. This appreciation is likely driven by a combination of market performance in underlying holdings and active capital reallocation. The firm’s activity this quarter was decisive, characterized by a "survival-of-the-fittest" approach where capital was consolidated into existing winners while underperforming or thesis-complete positions were liquidated.

Key Holdings

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
PBLS
PARABILIS MEDICINES INC
$176M6.4M16.0%
02
BEAM
BEAM THERAPEUTICS INC
$156M4.5M14.2%
03
RAPP
RAPPORT THERAPEUTICS INC
$155M3.7M14.1%
04
SPTX
SEAPORT THERAPEUTICS INC
$137M6.3M12.4%
05
ERAS
ERASCA INC
$130M7.1M11.8%
06
VIR
VIR BIOTECHNOLOGY INC
$129M12.7M11.8%
07
MAZE
MAZE THERAPEUTICS INC
$123M4.1M11.2%
08
LYEL
LYELL IMMUNOPHARMA INC
$46M3.2M4.1%
09
GENB
GENERATE BIOMEDICINES INC
$33M1.9M3.0%
10
TXG
10X GENOMICS INC
$8M218K0.8%

Filing history

2026Q2Jun 30
$1.1B▲ 62.5%
12 positionsView →
2026Q1Mar 31
$677M▲ 3.9%
10 positionsView →
2025Q4Dec 31
$652M▲ 69.3%
9 positionsView →
2025Q3Sep 30
$385M▲ 28.7%
7 positionsView →
2025Q2Jun 30
$299M▲ 86.6%
11 positionsLocked
2025Q1Mar 31
$160M▼ 30.4%
7 positionsLocked
2024Q4Dec 31
$230M▼ 11.6%
9 positionsLocked
2024Q3Sep 30
$261M▼ 2.1%
9 positionsLocked
2024Q2Jun 30
$266M▲ 231.4%
9 positionsLocked
2024Q1Mar 31
$80M▼ 50.9%
8 positionsLocked
2023Q4Dec 31
$164M▲ 6.2%
7 positionsLocked
2023Q3Sep 30
$154M▼ 4.9%
7 positionsLocked
Showing 12 of 27